Background and aims Vedolizumab is a gut-selective anti-integrin (alpha(4)beta(7)) antibody for the treatment of inflammatory bowel disease with a well-known optimal safety profile. We aimed to compare its risk of infections with that of anti-TNF drugs and ustekinumab in patients with both ulcerative colitis and Crohn's disease.Methods All Crohn's disease and ulcerative colitis patients undergoing biological treatment at our centre between 2013 and 2019 were retrospectively included. All infectious complications were registered, considering both inpatient and outpatient events. A comparison of the exposure-adjusted infection rates of vedolizumab, anti-TNF drugs and ustekinumab was carried out, with a specific focus on the rate of gut infections. All infection rates were expressed in events per patient-years (PYs).Results The overall exposure-adjusted infection rate was 11.5/100 PYs. The most common infections were respiratory tract infections, cutaneous infections, HSV infections/reactivations and gut infections. The rate of serious infections was 1.3/100 PYs. The infection rate of vedolizumab was 17.5/100 PYs, with Crohn's disease patients having a lower infection risk compared with ulcerative colitis patients (P = 0.035). Gut infections were observed in 3.0% of the whole patient population (1.5/100 PYs) and were more common in the vedolizumab group (P = 0.0001).Conclusions Our study confirms the good safety profile of vedolizumab. Among patients treated with vedolizumab, those with ulcerative colitis have a higher risk of developing infectious complications. Patients treated with vedolizumab have a higher risk of gut infections compared with patients treated with anti-TNF drugs or ustekinumab. Presumably, this is due to the gut-selective mechanism of action of vedolizumab. Copyright (C) 2021 Wolters Kluwer Health, Inc. All rights reserved.

Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease / Innocenti, Tommaso; Roselli, Jenny; Lynch, Erica N; Apolito, Pasquale; Parisio, Laura; Bagnoli, Siro; Macrì, Giuseppe; Rogai, Francesca; Tarocchi, Mirko; Milani, Stefano; Galli, Andrea; Milla, Monica; Dragoni, Gabriele. - In: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. - ISSN 0954-691X. - ELETTRONICO. - 33:(2021), pp. e574-e579. [10.1097/MEG.0000000000002166]

Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease

Innocenti, Tommaso;Roselli, Jenny;Lynch, Erica N;Apolito, Pasquale;Parisio, Laura;Rogai, Francesca;Tarocchi, Mirko;Milani, Stefano;Galli, Andrea;Milla, Monica;Dragoni, Gabriele
2021

Abstract

Background and aims Vedolizumab is a gut-selective anti-integrin (alpha(4)beta(7)) antibody for the treatment of inflammatory bowel disease with a well-known optimal safety profile. We aimed to compare its risk of infections with that of anti-TNF drugs and ustekinumab in patients with both ulcerative colitis and Crohn's disease.Methods All Crohn's disease and ulcerative colitis patients undergoing biological treatment at our centre between 2013 and 2019 were retrospectively included. All infectious complications were registered, considering both inpatient and outpatient events. A comparison of the exposure-adjusted infection rates of vedolizumab, anti-TNF drugs and ustekinumab was carried out, with a specific focus on the rate of gut infections. All infection rates were expressed in events per patient-years (PYs).Results The overall exposure-adjusted infection rate was 11.5/100 PYs. The most common infections were respiratory tract infections, cutaneous infections, HSV infections/reactivations and gut infections. The rate of serious infections was 1.3/100 PYs. The infection rate of vedolizumab was 17.5/100 PYs, with Crohn's disease patients having a lower infection risk compared with ulcerative colitis patients (P = 0.035). Gut infections were observed in 3.0% of the whole patient population (1.5/100 PYs) and were more common in the vedolizumab group (P = 0.0001).Conclusions Our study confirms the good safety profile of vedolizumab. Among patients treated with vedolizumab, those with ulcerative colitis have a higher risk of developing infectious complications. Patients treated with vedolizumab have a higher risk of gut infections compared with patients treated with anti-TNF drugs or ustekinumab. Presumably, this is due to the gut-selective mechanism of action of vedolizumab. Copyright (C) 2021 Wolters Kluwer Health, Inc. All rights reserved.
2021
33
e574
e579
Innocenti, Tommaso; Roselli, Jenny; Lynch, Erica N; Apolito, Pasquale; Parisio, Laura; Bagnoli, Siro; Macrì, Giuseppe; Rogai, Francesca; Tarocchi, Mirko; Milani, Stefano; Galli, Andrea; Milla, Monica; Dragoni, Gabriele
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1291392
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact